Subject(s)
Endoscopy, Digestive System , Gastric Bypass/adverse effects , Gastric Fistula , Obesity, Morbid/surgery , Reoperation , Septal Occluder Device , Wound Closure Techniques/instrumentation , Adult , Endoscopy, Digestive System/instrumentation , Endoscopy, Digestive System/methods , Equipment Design , Gastric Bypass/methods , Gastric Fistula/diagnostic imaging , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Gastric Fistula/surgery , Humans , Male , Reoperation/instrumentation , Reoperation/methods , Self Expandable Metallic Stents , Tomography, X-Ray Computed/methods , Treatment OutcomeSubject(s)
Cutaneous Fistula , Drainage/methods , Endosonography/methods , Gastric Bypass , Gastric Fistula , Paracentesis/methods , Adult , Bariatric Surgery/adverse effects , Bariatric Surgery/methods , Contrast Media/pharmacology , Cutaneous Fistula/diagnostic imaging , Cutaneous Fistula/physiopathology , Cutaneous Fistula/surgery , Gastric Bypass/adverse effects , Gastric Bypass/methods , Gastric Fistula/diagnostic imaging , Gastric Fistula/physiopathology , Gastric Fistula/surgery , Humans , Tomography, X-Ray Computed/methods , Treatment OutcomeSubject(s)
Cutaneous Fistula , Endoscopy, Gastrointestinal , Gastric Fistula , Gastrostomy/adverse effects , Surgical Instruments , Wound Closure Techniques/instrumentation , Adult , Cutaneous Fistula/physiopathology , Cutaneous Fistula/surgery , Endoscopy, Gastrointestinal/instrumentation , Endoscopy, Gastrointestinal/methods , Female , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Gastric Fistula/surgery , Humans , Treatment OutcomeABSTRACT
The management of gastric leak after laparoscopic sleeve gastrectomy (LSG) can be complex and challenging. Whilst operative interventions are mostly complicated and reserved for unstable or refractory cases, endoscopic self-expandable metal stenting (SEMS) is increasingly preferred as a safer treatment option. Yet, SEMS carries the problems of frequent stent migration and inconsistent healing as ordinary SEMS is designed mainly for stenotic disease. We hereby present two cases of early and chronic post-LSG leakage that were respectively failed to be treated by surgery and ordinary SEMS but were successfully managed by a dedicated extra-long oesophago-gastro-duodenal stent. In oesophago-gastro-duodenal stenting, the characteristics of extra-long stent length allow total gastric exclusion between the mid-oesophagus and the first part of duodenum to prevent stent migration and to equalise high pressure gradient within the gastric sleeve to promote fistula healing.
Subject(s)
Anastomotic Leak/surgery , Bariatric Surgery/adverse effects , Duodenum/surgery , Esophagus/surgery , Gastrectomy/adverse effects , Stents , Stomach/surgery , Anastomotic Leak/etiology , China , Female , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Humans , Laparoscopy/adverse effects , Metabolic Syndrome/complications , Middle Aged , Obesity, Morbid/complications , Obesity, Morbid/surgery , Self Expandable Metallic Stents/adverse effects , TrastuzumabSubject(s)
Gastric Fistula , Gastroscopy , Gastrostomy/adverse effects , Postoperative Complications , Dermatitis, Contact/etiology , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Gastric Fistula/surgery , Gastroscopy/instrumentation , Gastroscopy/methods , Gastrostomy/methods , Hemorrhage/etiology , Humans , Male , Middle Aged , Postoperative Complications/physiopathology , Postoperative Complications/surgery , Surgical Instruments , Treatment OutcomeSubject(s)
Humans , Male , Middle Aged , Gastrointestinal Hemorrhage/complications , Gastrointestinal Hemorrhage/surgery , Gastrointestinal Hemorrhage , Gastric Fistula/complications , Gastric Fistula , Anti-Bacterial Agents/therapeutic use , Hematemesis/complications , Hematemesis/surgery , Gastric Fistula/physiopathology , Splenic Artery/pathology , Splenic Artery , Lymphoma/complicationsSubject(s)
Anastomotic Leak/surgery , Bronchial Fistula/surgery , Gastrectomy/adverse effects , Gastric Fistula/surgery , Obesity, Morbid/surgery , Adult , Anastomotic Leak/diagnosis , Bariatric Surgery/adverse effects , Bariatric Surgery/methods , Body Mass Index , Bronchial Fistula/etiology , Disease Progression , Fatal Outcome , Female , Gastrectomy/methods , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Humans , Laparoscopy/adverse effects , Laparoscopy/methods , Obesity, Morbid/diagnosis , Postoperative Complications/diagnosis , Postoperative Complications/surgery , Reoperation/methods , Risk Assessment , Sampling Studies , Time Factors , Treatment OutcomeSubject(s)
Duodenal Ulcer/surgery , Gastric Fistula , Gastroenterostomy/adverse effects , Peptic Ulcer Perforation/surgery , Reoperation/methods , Stomach Ulcer , Adult , Duodenal Ulcer/physiopathology , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Gastric Fistula/surgery , Gastroenterostomy/methods , Humans , Male , Patient Acuity , Peptic Ulcer Perforation/etiology , Peptic Ulcer Perforation/physiopathology , Stomach/pathology , Stomach/surgery , Stomach Ulcer/etiology , Stomach Ulcer/physiopathology , Stomach Ulcer/surgery , Treatment OutcomeABSTRACT
BACKGROUND: In patients with a left ventricular assist device (LVAD), pump-related infection can cause adverse effects that may result in death. METHODS: We describe three patients who had infections related to a fistula between the gastrointestinal (GI) tract and the LVAD pocket and who subsequently underwent successful heart transplantation without developing sepsis. In no case did the LVAD-related infection adversely affect the outcome of transplantation. CONCLUSIONS: For detecting the fistulas, full upper-GI endoscopy and colonoscopy were superior to other types of diagnostic imaging studies.
Subject(s)
Gastric Fistula/complications , Heart Transplantation , Heart-Assist Devices/adverse effects , Intestinal Fistula/complications , Prosthesis-Related Infections/etiology , Adult , Combined Modality Therapy , Follow-Up Studies , Gastric Fistula/physiopathology , Heart Failure/diagnosis , Heart Failure/surgery , Humans , Intestinal Fistula/physiopathology , Male , Middle Aged , Prosthesis Design , Prosthesis-Related Infections/physiopathology , Prosthesis-Related Infections/therapy , Risk Assessment , Sampling Studies , Severity of Illness Index , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: The mainstay of therapy for gastrocutaneous (GC) fistulas has been surgical intervention. However, endoclips are currently used for management of perforations and fistulas but are limited by their ability to entrap and hold the tissue. OBJECTIVE: To report the first North American experience with a commercially available over-the-scope clip (OTSC) device, a novel and new tool for the endoscopic entrapment of tissue for the closure of fistula and perforations. METHODS: The present single-centre study was conducted at a tertiary referral academic gastroenterology unit and centre for advanced therapeutic endoscopy and involved patients referred for endoscopic treatment for the closure of a GC fistula. The OTSC device was mounted on the tip of the endoscope and passed into the stomach to the level of the fistula. The targeted site of the fistula was grasped with the tissue anchoring tripod and pulled into the cap with concomitant scope channel suction. Once the tissue was trapped in the cap, a 'bear claw' clip was deployed. RESULTS: The patients recovered with fistula closure. No complication or recurrence was noted. Fistula sizes >1 cm, however, were difficult to close with the OTSC system. The length of stay of the bear claw clip at the fistula site is unpredictable, which may lead to incomplete closure of the fistula. CONCLUSION: Closure of a GC fistula using a novel 'bear claw' clip system is feasible and safe.
Subject(s)
Cutaneous Fistula/surgery , Gastric Fistula/surgery , Gastroscopes/trends , Gastroscopy/instrumentation , Surgical Instruments/trends , Aged, 80 and over , Cutaneous Fistula/physiopathology , Equipment Design , Female , Gastric Fistula/physiopathology , Gastroscopy/adverse effects , Gastroscopy/methods , Gastroscopy/trends , Humans , Length of Stay , Treatment OutcomeABSTRACT
AIM: To evaluate measurements of intragastric pH with the Bravo capsule system over a prolonged time. METHODS: A Bravo capsule was placed inside the rat gastric body and pH was studied for periods up to five consecutive days. For comparison, a gastric fistula model was used. Effects of ghrelin and esomeprazole, with or without pentagastrin, on gastric pH were studied. In addition, effects of esomeprazole on plasma ghrelin, gastrin and somatostatin were analyzed. RESULTS: All rats recovered after surgery. The average 24-h pH during free feeding was 2.3 +/- 0.1 (n = 20) with a variation of 18% +/- 6% over 5 d. Ghrelin, 2400 pmol/kg, t.i.d. increased pH from 1.7 +/- 0.1 to 3.1 +/- 0.3 (P < 0.01) as recorded with the Bravo system. After esomeprazole (1 mg/kg, 3 mg/kg and 5 mg/kg) there was a dose-dependent pH increase of maximally 3.4 +/- 0.1, with day-to-day variation over the entire period of 8% +/- 3%. The fistula and pH studies generated similar results. Acid inhibition with esomeprazole increased plasma ghrelin from 10 +/- 2 pmol/L to 65 +/- 26 pmol/L (P < 0.001), and somatostatin from 10 +/- 2 pmol/L to 67 +/- 18 pmol/L (P < 0.001). CONCLUSION: pH measurements with the Bravo capsule are reliable, and comparable to those of the gastric fistula model. The Bravo system optimizes accurate intragastric pH monitoring over prolonged periods and allows both short- and long-term evaluation of effects of drugs and hormones.
Subject(s)
Capsule Endoscopes , Capsule Endoscopy , Gastric Acid/metabolism , Gastric Acidity Determination/instrumentation , Gastric Fistula/physiopathology , Gastric Mucosa/metabolism , Gastrointestinal Hormones/metabolism , Ghrelin/metabolism , Animals , Disease Models, Animal , Esomeprazole/pharmacology , Gastric Fistula/metabolism , Gastric Mucosa/drug effects , Gastrins/metabolism , Gastrointestinal Agents/pharmacology , Hydrogen-Ion Concentration , Male , Monitoring, Ambulatory/instrumentation , Pentagastrin/pharmacology , Proton Pump Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Somatostatin/metabolism , Telemetry/instrumentation , Time FactorsABSTRACT
The parabrachial nucleus (PBN) has been strongly associated with taste aversion learning (TAL) acquisition. Independent of its suggested associative functions, this brain stem centre plays a key role in the sensorial processing of both gustatory and visceral information. The sensory visceral functions have been attributed to the lateral area of the PBN (PBNl) but, recently, it has been proposed that within this area a form of anatomical and functional segregation may also exist, determined by factors such as, the learning paradigm used, the nature of aversive agent used, or the route chosen for the administration of this agent. This study used a lesion approach in rats to address the question of whether the dorsal most portion of the PBNl plays a key role in the acquisition of a conditioned avoidance to flavored stimuli induced by hypertonic sodium chloride (intra gastric), and whether this role is dependent on the flavor avoidance learning (FAL) paradigm used, concurrent (experiment 1) or delayed-sequential FAL (experiment 2). Results showed a clear disruptive effect of the PBNl electrolytic lesion on the acquisition of the concurrent FAL, but hardly any attenuation of the delayed-sequential FAL. This finding is discussed in the context of the hypothesis that two separate and apparently non-redundant routes exist for the processing of the visceral information.
Subject(s)
Avoidance Learning/physiology , Brain/physiology , Pons/physiology , Sodium Chloride , Taste , Animals , Brain Injuries/physiopathology , Drinking Behavior/physiology , Gastric Fistula/physiopathology , Habituation, Psychophysiologic , Humans , Male , Rats , Rats, Wistar , Water Deprivation/physiologyABSTRACT
Pancreatic pseudocyst is one of the common complications of acute and chronic pancreatitis and has variable natural history. We present a case of spontaneous resolution of a pancreatic pseudocyst with gastric connection. This case presented a 46-year-old man with a pancreatic pseudocyst resulting from a complication of acute pancreatitis. This resolved spontaneously through the formation of a fistula between the pseudocyst and stomach. The fistula tract was also occluded spontaneously and the patient recovered without any complication or need for surgical treatment. The patient has been good progress at a two year follow up after spontaneous resolution of the fistula.
Subject(s)
Gastric Fistula/physiopathology , Pancreatic Fistula/physiopathology , Pancreatic Pseudocyst/physiopathology , Acute Disease , Endoscopy, Digestive System , Gastric Fistula/etiology , Gastric Fistula/pathology , Humans , Male , Middle Aged , Pancreatic Fistula/etiology , Pancreatic Fistula/pathology , Pancreatic Pseudocyst/etiology , Pancreatic Pseudocyst/pathology , Pancreatitis, Alcoholic/complications , Remission, Spontaneous , Tomography, X-Ray ComputedABSTRACT
BACKGROUND/PURPOSE: Few reports have documented the rate of persistence of a gastrocutaneous fistula (GCF) after gastrostomy removal or the reason for the persistence of a GCF. The purpose of this report was to analyze a large group of pediatric patients with a persistent GCF to determine the rate of persistence and any factors that correlate with the persistence of a GCF. METHODS: This was a retrospective review of 1,042 children from The Children's Hospital, Denver, Colorado who had a gastrostomy constructed between 1992 and 2002. The charts of all children with a persistent GCF after gastrostomy catheter removal were analyzed for correlation between 13 clinical parameters and the persistence of a GCF. RESULTS: There were 150 children with a persistent GCF for an incidence of 34%. Time elapsed between the creation of the GCF and removal of the gastrostomy appliance (< or =8 months versus >8 months) was the only parameter that showed any correlation with persistence of a GCF (P <.05). None of the other parameters studied showed any conclusive correlation with persistence of a GCF. CONCLUSIONS: Time was the only factor that determined whether a surgically created GCF would persist after removal of a gastrostomy appliance.
Subject(s)
Gastrostomy/adverse effects , Wound Healing , Child , Child, Preschool , Cutaneous Fistula/etiology , Cutaneous Fistula/physiopathology , Device Removal , Enteral Nutrition/methods , Female , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Gastrostomy/instrumentation , Humans , Infant , Laparoscopy , Male , Retrospective Studies , Risk FactorsABSTRACT
The effects of a new benzimidazole derivative, ME3407 (n-butyl-2-(thiazolo-[5,4-b]pyrid-2-yl) sulfinylacetate, CAS 133903-90-9), on gastric acid secretion and gastric and duodenal ulcers in rats were examined. ME3407, given orally, inhibited dose-dependently (0.3-30 mg/kg) the incidence of gastric lesions such as Shay ulcers, and water-immersion stress-, acetylsalicylic acid (ASA)- and histamine-induced erosions. In addition, ME3407 showed marked therapeutic effect on HCl- and ASA-induced lesions. In the lumen-perfused rats, oral administration of ME3407 inhibited dose-dependently (1-100 mg/kg) gastric acid secretion induced by histamine and tetragastrin with ED50 values of 3.02 and 3.37 mg/kg, respectively. Oral administration of ME3407 at a dose of 30 mg/kg also inhibited the elevation of serum gastrin level. The development of duodenal ulcers caused by mepirizole and systeamine was also potently inhibited by ME3407 at an oral dose of 0.1-30 mg/kg. However, when given at 30 mg/kg intraduodenally, subcutaneously or intravenously, ME3407 did not inhibit these acutely induced gastric elosion and acid output. ME3407 was not detected in the serum upon oral administration. These results indicated that ME3407 was active only by oral administration, and exerts direct action on the ulcers and acid secretion from the gastric membrane.
Subject(s)
Anti-Ulcer Agents/pharmacology , Benzimidazoles/pharmacology , Gastric Acid/metabolism , Gastric Mucosa/metabolism , Pyridines/pharmacology , Thiazoles/pharmacology , Animals , Anti-Inflammatory Agents , Aspirin , Cysteamine , Duodenal Ulcer/chemically induced , Duodenal Ulcer/prevention & control , Epirizole , Gastric Fistula/physiopathology , Gastric Mucosa/drug effects , Gastrins/blood , Histamine , Immersion/adverse effects , Indomethacin , Male , Pepsin A/metabolism , Pylorus/physiology , Rats , Stomach Ulcer/chemically induced , Stomach Ulcer/prevention & controlABSTRACT
Leptin released by adipocytes has been implicated in the control of food intake but recent detection of specific leptin receptors in the pancreas suggests that this peptide may also play some role in the modulation of pancreatic function. This study was undertaken to examine the effect of exogenous leptin on pancreatic enzyme secretion in vitro using isolated pancreatic acini, or in vivo in conscious rats with chronic pancreatic fistulae. Leptin plasma level was measured by radioimmunoassay following leptin administration to the animals. Intraperitoneal (i.p.) administration of leptin (0.1, 1, 5, 10, 20 or 50 microg/kg), failed to affect significantly basal secretion of pancreatic protein, but markedly reduced that stimulated by feeding. The strongest inhibition has been observed at dose of 10 microg/kg of leptin. Under basal conditions plasma leptin level averaged about 0.15 +/- 0.04 ng/ml and was increased by feeding up to 1.8 +/- 0.4 ng/ml. Administration of leptin dose-dependently augmented this plasma leptin level, reaching about 0.65 +/- 0.04 ng/ml at dose of 10 microg/kg of leptin. This dose of leptin completely abolished increase of pancreatic protein output produced by ordinary feeding, sham feeding or by diversion of pancreatic juice to the exterior. Leptin (10(-10)-10(-7) M) also dose-dependently attenuated caerulein-induced amylase release from isolated pancreatic acini, whereas basal enzyme secretion was unaffected. We conclude that leptin could take a part in the inhibition of postprandial pancreatic secretion and this effect could be related, at least in part, to the direct action of this peptide on pancreatic acini.
Subject(s)
Leptin/physiology , Pancreas/metabolism , Postprandial Period/physiology , Animals , Bethanechol Compounds/pharmacology , Ceruletide/pharmacology , Chronic Disease , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Evaluation, Preclinical/methods , Drug Therapy, Combination , Eating/physiology , Gastric Fistula/etiology , Gastric Fistula/physiopathology , Injections, Intraperitoneal , Leptin/blood , Leptin/pharmacology , Pancreas/cytology , Pancreas/drug effects , Pancreatic Fistula/etiology , Pancreatic Fistula/physiopathology , Pancreatic Juice/drug effects , Pancreatic Juice/enzymology , Pancreatic Juice/metabolism , Postprandial Period/drug effects , Rats , Rats, WistarABSTRACT
Our aim was to determine the mechanisms by which intraileal fat alters proximal gastrointestinal motility--the ileal brake. Five mongrel dogs with ileal Thiry-Vella fistulas were equipped with strain gauge force transducers on the upper gut to measure contractile activity. Ileal infusions of 115 mmol/L oleic acid and triglyceride were studied in dogs with extrinsically innervated and extrinsically denervated Thiry-Vella loops. Plasma concentrations of peptide YY and total glucagon-like immunoactivity were measured. Oleic acid but not triglyceride inhibited postprandial contractions in the gastric antrum in dogs with innervated and denervated Thiry-Vella loops. Postprandial duodenal and jejunal motility was inhibited by oleic acid regardless of extrinsic denervation to the loops (P <0.05), but triglyceride inhibited small intestinal motility only in dogs with innervated Thiry-Vella loops. Intraileal oleic acid but not triglyceride increased plasma concentrations of peptide YY and total glucagon-like immunoactivity in dogs with innervated and denervated Thiry-Vella loops. Intraileal oleic acid inhibits gastric and small intestinal motility possibly via increased plasma concentrations of peptide YY and enteroglucagon. Intact extrinsic innervation is necessary for intraileal triglyceride to inhibit small intestinal motility.